12:00 AM
May 06, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

PharmaMar, J&J sales and marketing update

PharmaMar said the commercial supply of cancer drug Caelyx pegylated liposomal doxorubicin from Johnson & Johnson has been restored in the EU, along with Liechtenstein, Norway and Switzerland. In November 2011, EMA's CHMP said no new patients should be treated with Caelyx after identifying "shortcomings" at the liposomal doxorubicin's sole EU manufacturing site, particularly with the aseptic filling process. As...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >